GlassScriptPhysician profile
Lubna M Zuberi
NPI 1558558304
$699.79
in general payments reported to CMS, 2019-2025
17 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $12.10 · 2021: $19.71 · 2022: $41.55 · 2023: $27.76 · 2024: $16.93 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.20 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $149.58 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $86.42 | 2019-2020 | |
| Novo Nordisk INC | $59.36 | 2019-2025 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.62 | 2019 | |
| Medtronic Minimed, INC. | $40.73 | 2019 | |
| Merck Sharp & Dohme LLC | $39.96 | 2019 | |
| Senseonics, Incorporated | $34.00 | 2019 | |
| Lifescan, INC. | $30.81 | 2019 | |
| Kyowa Kirin, INC. | $29.30 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.49 | 2019 | |
| Dexcom, INC. | $27.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.93 | 2019 | |
| Atricure, INC. | $25.82 | 2025 | Atriclip Laa Exclusion System |
| Corcept Therapeutics | $19.71 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.98 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $15.98 | 2019 | |
| Becton, Dickinson and Company | $15.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lubna Zuberi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.